FIH to POC. Fast.
Translational Pharmaceutics®: For FIH programs
to achieve POC milestone
in upfront chemistry, manufacturing, and controls (CMC)
and flexibility in your study
based on emerging clinical data
Customizes drug product
supply to the needs of your study
and streamlines delivery
Accelerating FIH to POC: What our customers say
R552 is a potent and selective RIP1 kinase inhibitor that blocks inflammatory cell death downstream of death receptors. It is being developed at Rigel Pharmaceuticals for treatment of autoimmune and inflammatory disorders. We were very delighted to have Quotient Sciences on board and they worked with us on the formulation development as well as the first-in-human study of R552. During the course of project development, we were very impressed by Quotient Sciences’ responsiveness in communication, efficiency/flexibility in project management, extensive knowledge/experience in formulation development, early-phase clinical trial conduct, and safety monitoring. Quotient Sciences is one of the best development partners that we have ever worked with and would recommend it for future collaborations without any reservation.